Other medications linked to MRONJ development are denosumab [25], an anti-resorptive which prevents bone resorption by inhibiting Receptor activator of nuclear factor kappa-β ligand (RANKL), and with a risk of MRONJ comparable to ZA [1], and anti-angiogenic medications prescribed as cancer treatments, such as sunitinib (a tyrosine kinase inhibitor) and bevacizumab (a vascular endothelial growth factor (VEGF) inhibitor) [26]. This evidence concerns the gene TNFSF11 and cancer.